Indeed, while some studies have shown a link to ISR in ALS, others have shown that therapeutic targeting of the ISR in SOD1 forms of ALS may, in fact, aggravate disease onset (Marlin et al, 2022). The gene discussed is SOD1; the disease is amyotrophic lateral sclerosis.